Published in Blood on December 01, 1993
LTB4 is a signal-relay molecule during neutrophil chemotaxis. Dev Cell (2012) 1.62
Diminished adhesion of Anaplasma phagocytophilum-infected neutrophils to endothelial cells is associated with reduced expression of leukocyte surface selectin. Infect Immun (2003) 1.20
Modeling the reversible kinetics of neutrophil aggregation under hydrodynamic shear. Biophys J (1997) 1.06
Neutrophil swarming toward Cryptococcus neoformans is mediated by complement and leukotriene B4. Biochem Biophys Res Commun (2016) 0.75
Human platelet size, shape, and related functions in health and disease. Physiol Rev (1982) 1.52
Geometry of normal mammalian platelets by quantitative microscopic studies. Biophys J (1976) 1.29
Rheo-optical transients in erythrocyte suspensions. Biochem Biophys Res Commun (1975) 1.18
Efficiency of platelet adhesion to fibrinogen depends on both cell activation and flow. Biophys J (2000) 1.08
Microscopic measurements of platelet aggregation reveal a low ADP-dependent process distinct from turbidometrically measured aggregation. J Lab Clin Med (1983) 1.04
Platelet aggregation in laminar flow. I. Adenosine diphosphate concentration, time and shear rate dependence. Thromb Res (1982) 0.98
Ligand bridging mediates integrin alpha IIb beta 3 (platelet GPIIB-IIIA) dependent homotypic and heterotypic cell-cell interactions. J Clin Invest (1991) 0.98
The microrheology of mammalian platelets: studies of rheo-optical transients and flow in tubes. Microvasc Res (1976) 0.97
Adrenaline and adenosine diphosphate-induced platelet aggregation require shape change. Importance of pseudopods. J Lab Clin Med (1984) 0.95
Time and force dependence of the rupture of glycoprotein IIb-IIIa-fibrinogen bonds between latex spheres. Biophys J (2000) 0.95
Adenosine diphosphate-induced aggregation of human platelets in flow through tubes: III. Shear and extrinsic fibrinogen-dependent effects. Thromb Haemost (1994) 0.93
Physical, chemical and functional changes following platelet activation in normal and "giant" platelets. Blood Cells (1983) 0.93
Differential inhibition of the platelet activation sequence: shape change, micro- and macro-aggregation, by a stable prostacyclin analogue (Iloprost). Thromb Haemost (1988) 0.92
Role of the gamma chain Ala-Gly-Asp-Val and Aalpha chain Arg-Gly-Asp-Ser sites of fibrinogen in coaggregation of platelets and fibrinogen-coated beads. Biochim Biophys Acta (1998) 0.91
Turbidometric evaluations of platelet activation: relative contributions of measured shape change, volume, and early aggregation. J Pharmacol Methods (1983) 0.91
Platelets from "giant platelet syndrome (BSS)" are discocytes and normal sized. J Lab Clin Med (1978) 0.91
A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen, and GPIIbIIIa receptor. J Biol Chem (2000) 0.91
Platelet aggregation measured in vitro by microscopic and electronic particle counting. Methods Enzymol (1989) 0.91
Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haematol (1996) 0.90
Shape-changing agents produce abnormally large platelets in a hereditary "giant platelets syndrome (MPS)". J Lab Clin Med (1979) 0.90
Aggregation efficiency of activated normal or fixed platelets in a simple shear field: effect of shear and fibrinogen occupancy. Biophys J (1994) 0.89
Blood cell structure-function studies: light transmission and attenuation coefficients of suspensions of blood cells and model particles at rest and with stirring. J Lab Clin Med (1975) 0.88
Platelet size and shape in hereditary giant platelet syndromes on blood smear and in suspension: evidence for two types of abnormalities. J Lab Clin Med (1985) 0.86
Determination of adhesion force between single cell pairs generated by activated GpIIb-IIIa receptors. Blood (1993) 0.85
Dynamics of human neutrophil aggregation evaluated by flow cytometry. J Leukoc Biol (1991) 0.85
Platelets from bleeding Simmental cattle mobilize calcium, phosphorylate myosin light chain and bind normal numbers of fibrinogen molecules but have abnormal cytoskeletal assembly and aggregation in response to ADP. Thromb Haemost (1994) 0.85
A model for the recruitment of neutrophils at sites of inflammation. Physiological relevance of in vivo neutrophil aggregation. Med Hypotheses (1992) 0.84
Kinetics of ADP-induced human platelet shape change: apparent positive cooperativity. Can J Physiol Pharmacol (1980) 0.84
Inhibition of platelet function by antithrombotic agents which selectively inhibit low-Km cyclic 3',5'-adenosine monophosphate phosphodiesterase. J Lab Clin Med (1980) 0.83
The effects of pCO2 and pH on platelet shape change and aggregation for human and rabbit platelet-rich plasma. Thromb Res (1977) 0.83
Invaginated plasma membrane of human platelets: evagination and measurement in normal and "giant" platelets. J Lab Clin Med (1979) 0.81
Montreal platelet syndrome: a defect in calcium-activated neutral proteinase (calpain). Blood (1989) 0.81
Quantitative parameterization of the light transmission properties of citrated, platelet-rich plasma as a function of platelet and adenosine diphosphate concentrations and temperature. J Lab Clin Med (1973) 0.80
Unusual properties of platelet shape in coronary and cerebral artery disease. Thromb Res (1987) 0.80
Ristocetin- and thrombin-induced platelet aggregation at physiological shear rates: differential roles for GPIb and GPIIb-IIIa receptor. Thromb Haemost (1998) 0.80
Rheo-optical studies of blood cells. Biorheology (1975) 0.79
Rheooptical studies of platelet structure and function. Prog Hemost Thromb (1978) 0.77
Platelets in suspension require preactivation to adhere to immobilized fibrinogen. Ann N Y Acad Sci (2001) 0.77
The fibrinogen RIBS-I epitope (gamma373-385) appears proximate to the gamma408-411 adhesive domain but is not involved in interaction between receptor-bound or surface-adsorbed fibrinogen and platelet GPIIbIIIa. Biochim Biophys Acta (1998) 0.77
Polyfunctional properties of hybridoma lupus anticoagulant antibodies. J Rheumatol Suppl (1987) 0.76
Complementary roles for fibrin(ogen), thrombospondin and vWF in mediating shear-dependent aggregation of platelets stimulated at threshold thrombin concentrations. Thromb Haemost (2001) 0.76
Spontaneous platelet aggregation in a hereditary giant platelet syndrome (MPS). Am J Pathol (1984) 0.75
Reversal of acute experimental cerebral vasospasm by calcium antagonism with verapamil. Can J Neurol Sci (1984) 0.75
Inhibition of platelet aggregation by an SLE-derived human hybridoma autoantibody against an activation-dependent antigen. Thromb Haemost (1995) 0.75
Characteristics of the major platelet membrane site used in binding to collagen. Thromb Res (1979) 0.75
ATP does not affect fibrinogen binding to platelet GPIIbIIIa in systems free of signal transduction. Platelets (1999) 0.75
Dependency of platelet aggregation in vitro on the degree of platelet activation and shear rates. Thromb Haemost (1982) 0.75
Platelet adhesion to collagen is inhibited by adenosine diphosphate but unaffected by cell shape. Thromb Haemost (1981) 0.75
Thrombin receptor occupancy modulates aggregation efficiency and platelet surface expression of vWF and thrombospondin at low thrombin concentrations. Thromb Haemost (1999) 0.75
Sex-related differences in platelet morphology in whole blood (WB) and platelet-rich plasma (PRP). Thromb Res (1983) 0.75
Glycoprotein IIb-IIIa-liposomes bind fibrinogen but do not undergo fibrinogen-mediated aggregation. Platelets (2000) 0.75
The effects of calcium antagonism on the epicerebral circulation in early vasospasm. Stroke (1985) 0.75
Effect of adenosine 5'-diphosphate and shape change on 5-hydroxytryptamine uptake by human blood platelets. Thromb Res (1980) 0.75
The kinetics of thrombin- and SFLLRN-induced aggregation of human platelets in flow through tubes. Biorheology (1999) 0.75
Platelet aggregation in laminar flow. II. Shear rate and ADP-dependent effects of acetylsalicylic acid and indomethacin. Thromb Res (1982) 0.75
p32, a platelet autoantigen recognized by an SLE-derived autoantibody that inhibits platelet aggregation. J Autoimmun (1995) 0.75